- For Experts
Quantum computing might be the newest buzzword, but it also might represent the chief disruptive technology through 2040. Forward-looking leaders in biopharma R&D will appreciate Boston Consulting Group’s white paper outlining quantum computing’s potential uses and impacts in drug development. Matt Langione, Jean-François Bobier, Chris Meier, Sebastian Hasenfuss and Ulrik Schulze outline the technology’s potential and urge biopharma leaders to begin preparing now.
About the Authors
Matt Langione is a project leader, Jean-François Bobier is a partner and associate director, Christoph Meier is a principal, and Sebastian Hasenfuss is a consultant at the Boston Consulting Group. Ulrik Schulze, a managing director and senior partner at BCG, leads the firm’s global biopharmaceutical sector.